Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1979 Nov;38(2):231–234.

Lymphocyte transformation test with rabbit liver specific lipoprotein (RLSP) in chronic active hepatitis.

L Ortona, V Laghi, R Cauda, P Nervo
PMCID: PMC1537866  PMID: 527260

Abstract

Cellular sensitization to rabbit liver specific lipoprotein (RLSP) has been investigated using a lymphocyte transformation test in patients with chronic active hepatitis (CAH). A stimulation index greater than 2 was recorded in twenty out of twenty-five cases (eight of ten HBsAg positive and twelve of fiteen HBsAg negative) while values were lower than 2 in all the normal subjects. These results confirm the finding of sensitization to LSP in chronic active hepatitis irrespective of HBsAg status and show that rabbit LSP can be used as an alternative to the human antigen in the lymphocyte transformation test, and is further evidence that this liver membrane lipoprotein has antigenic determinants which have species-cross-reactivity.

Full text

PDF
232

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Büschenfelde K. H., Kössling F. K., Miescher P. A. Experimental chronic active hepatitis in rabbits following immunization with human liver proteins. Clin Exp Immunol. 1972 May;11(1):99–108. [PMC free article] [PubMed] [Google Scholar]
  2. Cochrane A. M., Moussouros A., Thomsom A. D., Eddleston A. L., Wiiliams R. Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet. 1976 Feb 28;1(7957):441–444. doi: 10.1016/s0140-6736(76)91472-0. [DOI] [PubMed] [Google Scholar]
  3. De Groote J., Desmet V. J., Gedigk P., Korb G., Popper H., Poulsen H., Scheuer P. J., Schmid M., Thaler H., Uehlinger E. A classification of chronic hepatitis. Lancet. 1968 Sep 14;2(7568):626–628. doi: 10.1016/s0140-6736(68)90710-1. [DOI] [PubMed] [Google Scholar]
  4. Eddleston A. L., Williams R. Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet. 1974 Dec 28;2(7896):1543–1545. doi: 10.1016/s0140-6736(74)90287-6. [DOI] [PubMed] [Google Scholar]
  5. Facchini A., Stefanini G. F., Bernardi M., Miglio F., Gasbarrini G., Labö G. Lymphocytotoxicity test against rabbit hepatocytes in chronic liver diseases. Gut. 1978 Mar;19(3):189–193. doi: 10.1136/gut.19.3.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fernandez-Cruz E., Escartin P., Bootello A., Kreisler M., Segovia de Arana J. M. Hepatocyte damage induced by lymphocytes from patients with chronic liver diseases, as detected by LDH release. Clin Exp Immunol. 1978 Mar;31(3):436–442. [PMC free article] [PubMed] [Google Scholar]
  7. Geubel A. P., Keller R. H., Summerskill W. H., Dickson E. R., Tomasi T. B., Shorter R. G. Lymphocyte cytotoxicity and inhibition studied with autologous liver cells: observations in chronic active liver disease and the primary biliary cirrhosis syndrome. Gastroenterology. 1976 Sep;71(3):450–456. [PubMed] [Google Scholar]
  8. Hopf U., Meyer zum Büschenfelde K. H., Freudenberg J. Liver-specific antigens of different species. II. Localization of a membrane antigen at cell surface of isolated hepatocytes. Clin Exp Immunol. 1974 Jan;16(1):117–123. [PMC free article] [PubMed] [Google Scholar]
  9. Hütteroth T. H., Meyer zum Büschenfelde K. H. Clinical relevance of the liver-specific lipoprotein (lsp). Acta Hepatogastroenterol (Stuttg) 1978 Jun;25(3):243–253. [PubMed] [Google Scholar]
  10. Kawanishi H. In vitro studies on IgG-mediated lymphocyte cytotoxicity in chronic active liver disease. Gastroenterology. 1977 Sep;73(3):549–555. [PubMed] [Google Scholar]
  11. Lee W. M., Reed W. D., Mitchell C. G., Galbraith R. M., Eddleston A. L., Zuckerman A. J., Williams R. Cellular and humoral immunity to hepatitis-B surface antigen in active chronic hepatitis. Br Med J. 1975 Mar 29;1(5960):705–708. doi: 10.1136/bmj.1.5960.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McFarlane I. G., Wojcicka B. M., Zucker G. M., Eddleston A. L., Williams R. Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol. 1977 Mar;27(3):381–390. [PMC free article] [PubMed] [Google Scholar]
  13. Meyer zum Büschenfelde K. H., Alberti A., Arnold W., Freudenberg J. Organ-specificity and diagnostic value of cell-mediated immunity against a liver-specific membrane protein: studies in hepatic and non-hepatic diseases. Klin Wochenschr. 1975 Nov 15;53(22):1061–1067. doi: 10.1007/BF01614382. [DOI] [PubMed] [Google Scholar]
  14. Miller J., Smith M. G., Mitchell C. G., Reed W. D., Eddleston A. L., Williams R. Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet. 1972 Aug 12;2(7772):296–297. doi: 10.1016/s0140-6736(72)92904-2. [DOI] [PubMed] [Google Scholar]
  15. Paronetto F., Vernace S. Immunological studies in patients with chronic active hepatitis. Cytotoxic activity of lymphocytes to autochthonous liver cells grown in tissue culture. Clin Exp Immunol. 1975 Jan;19(1):99–104. [PMC free article] [PubMed] [Google Scholar]
  16. Smith M. G., Golding P. L., Eddleston A. L., Mitchell C. G., Kemp A., Williams R. Cell-mediated immune responses in chronic liver diseases. Br Med J. 1972 Feb 26;1(5799):527–530. doi: 10.1136/bmj.1.5799.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Thestrup-Pedersen K., Ladefoged K., Andersen P. Lymphocyte transformation test with liver-specific protein and phytohaemagglutinin in patients with liver disease. Clin Exp Immunol. 1976 Apr;24(1):1–8. [PMC free article] [PubMed] [Google Scholar]
  18. Thomson A. D., Cochrane M. A., McFarlane I. G., Eddleston A. L., Williams R. Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature. 1974 Dec 20;252(5485):721–722. doi: 10.1038/252721a0. [DOI] [PubMed] [Google Scholar]
  19. Vierling J. M., Nelson D. L., Strober W., Bundy D. M., Jones E. A. In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis. J Clin Invest. 1977 Nov;60(5):1116–1128. doi: 10.1172/JCI108863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Vogten A. J., Hadzic N., Shorter R. G., Summerskill W. H., Taylor W. F. Cell-mediated cytotoxicity in chronic active liver disease: a new test system. Gastroenterology. 1978 May;74(5 Pt 1):883–889. [PubMed] [Google Scholar]
  21. Wands J. R., Perrotto J. L., Alpert E., Isselbacher K. J. Cell-mediated immunity in acute and chronic hepatitis. J Clin Invest. 1975 May;55(5):921–929. doi: 10.1172/JCI108021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wands K. R., Isselbacher K. J. Lymphocyte cytotoxicity to autologous liver cells in chronic active hepatitis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1301–1303. doi: 10.1073/pnas.72.4.1301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. von Meyer zum Büschenfelde K. H., Knolle J., Berger J. Celluläre Immunreaktionen gegenüber homologen leberspezifischen Antigenen (HLP) bei chronischen Leberentzündungen. Klin Wochenschr. 1974 Mar 1;52(5):246–248. doi: 10.1007/BF01468598. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES